文献速递脊柱外科骨质疏松与代谢性骨病

非内固定脊柱融合术后全身应用甲状旁腺激素对老年退变性腰椎滑脱患者融合率及融合骨块的影响:与安慰剂比较

Does Systemic Administration of Parathyroid Hormone After Noninstrumented Spinal Fusion Surgery Improve Fusion Rates and Fusion Mass in Elderly Patients Compared to Placebo in Patients With Degenerative Lumbar Spondylolisthesis?
PubMed 文献 · Spine (Phila Pa 1976) · 2019-01-01

一项前瞻性随机双盲安慰剂对照临床试验,纳入拟行非内固定后外侧融合的退变性腰椎滑脱患者,随机接受90天皮下注射20 μg特立帕肽(N=41)或安慰剂(N=46)。12个月术后薄层CT显示,两组融合率、融合骨块平均体积及坚固程度相似,特立帕肽未较安慰剂增加融合体积或改善融合骨块质量。

要点

  • 90天皮下注射20 μg特立帕肽耐受良好,但较安慰剂无额外获益。
  • 特立帕肽组与安慰剂组的融合率、融合骨块平均体积及坚固程度相似。
  • 在非内固定脊柱融合术后老年退变性腰椎滑脱患者中,特立帕肽未增加融合体积或改善融合骨块质量。

核心结论

  • 90天皮下注射20 μg特立帕肽未较安慰剂增加融合体积或改善融合骨块质量,研究人群为因退变性腰椎滑脱行非内固定脊柱融合术的老年患者。

研究设计与样本

  • 前瞻性、随机、双盲、安慰剂对照临床试验,纳入拟行非内固定后外侧融合的退变性腰椎滑脱患者,随机接受90天皮下注射20 μg特立帕肽(N=41)或安慰剂(N=46),按1:1比例分组。

主要发现

  • 两组在年龄、性别和手术节段数方面具有可比性。
  • 特立帕肽治疗耐受良好,但较安慰剂无额外获益。
  • 特立帕肽组与安慰剂组的融合率、融合骨块平均体积及坚固程度相似。

关键数值与推荐

  • 融合体积与质量通过术后12个月薄层计算机断层扫描(CT)评估。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY DESIGN: Prospective, randomized, double-blinded, placebo-controlled clinical trial. OBJECTIVE: To evaluate whether 90-day subcutaneous injections with 20 μg teriparatide increases the volume and quality of the fusion mass compared to placebo based on 12-month postop fine cut computed tomography scans. The secondary objective is to evaluate whether parathyroid hormone (PTH) increases fusion rates compared to placebo. SUMMARY OF BACKGROUND DATA: Few studies have investigated the effects of PTH on fusion in patients undergoing spinal arthrodesis. Early studies showed a more robust fusion mass with PTH after spinal fusion surgery. But the efficiency of PTH on noninstrumented spinal fusion surgery remains unclear. METHODS: Patients with degenerative spondylolisthesis scheduled for noninstrumented posterolateral fusion were randomized to receive 90-day subcutaneous injections with 20 μg teriparatide (N = 41) or placebo (N = 46) in a 1:1 fashion. Fusion volume and quality was evaluated using 12-month postoperative fine cut computed tomography scans. RESULTS: The two groups were comparable in terms of age, sex, and numbers of levels operated. PTH treatment was well tolerated but provided no additional benefit versus placebo. Fusion rates, the mean volume, and robustness of the fusion mass were similar between the PTH and placebo groups. CONCLUSION: Ninety-day subcutaneous administration of 20 μg teriparatide did not increase fusion volume or improve the quality of the fusion mass in elderly patients compared to placebo after noninstrumented spinal fusion surgery for degenerative spondylolisthesis. LEVEL OF EVIDENCE: 1.

来源:Spine (Phila Pa 1976),查看原文。版权归原作者所有。

引用

  1. Jespersen AB, Andresen ADK, Jacobsen MK, et al. Does Systemic Administration of Parathyroid Hormone After Noninstrumented Spinal Fusion Surgery Improve Fusion Rates and Fusion Mass in Elderly Patients Compared to Placebo in Patients With Degenerative Lumbar Spondylolisthesis? Spine (Phila Pa 1976). 2019. PMID: 30005049. doi:10.1097/BRS.0000000000002791

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。